{"product_id":"collegiumpharma-business-model-canvas","title":"Collegium Pharmaceutical Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Pharmaceutical: Compact Business Model Canvas \u0026amp; Investor Playbook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Collegium Pharmaceutical’s business model—this concise Business Model Canvas maps value propositions, customer segments, key partnerships, and revenue drivers to reveal how the company competes and scales; download the full Word\/Excel canvas for a section-by-section breakdown ideal for investors, consultants, and founders seeking actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical outsources production of its complex DETERx (extended‑release abuse‑deterrent) formulations to strategic contract manufacturing organizations (CMOs), enabling scalable output—Collegium reported COGS of $85.4M in 2024 while maintaining FDA compliance across all sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMajor Pharmaceutical Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium relies on major wholesalers—AmerisourceBergen, Cardinal Health, McKesson—to handle nationwide logistics and delivery, enabling reach to ~60,000 US pharmacies and facilities; these partners processed a large share of opioid and non-opioid Rx distribution volumes in 2024. \u003c\/p\u003e\n\u003cp\u003eKeeping strong credit lines and service SLAs with these distributors is vital: a one-week supply disruption could cut quarterly revenues by double digits given Collegium’s concentrated channel footprint and inventory turns. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with payers and PBMs secure formulary placement for Xtampza ER and Belbuca through rebate deals and value-based contracts; in 2024 Collegium reported payer discounts cutting list-price realization by ~30%, with PBM-preferred status correlating to a ~40% higher script share. Effective negotiation and contract management therefore drive net realized price and market share. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium partners with top academic and clinical research centers to run clinical trials and post-marketing studies that produced key data for approvals and label extensions; in 2024 these collaborations supported \u0026gt;15 studies and helped sustain combined R\u0026amp;D spend of $67.4M.\u003c\/p\u003e\n\u003cp\u003eThese partnerships validate safety and efficacy for its abuse-deterrent opioid portfolio, strengthening market differentiation and payer coverage through peer-reviewed evidence and real-world outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupported \u0026gt;15 studies in 2024\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend $67.4M (2024)\u003c\/li\u003e\n\u003cli\u003eEvidence drove label updates and payer discussions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisition and Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium fuels inorganic growth by acquiring or licensing products to broaden its CNS and pain portfolio; the 2021 acquisition of Ironshore Pharmaceuticals added ADHD assets and contributed to a revenue base that reached $141.6M in FY2023, supporting pipeline expansion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisitions\/licensing drive diversification\u003c\/li\u003e\n\u003cli\u003eIronshore deal added ADHD assets (2021)\u003c\/li\u003e\n\u003cli\u003eFY2023 revenue $141.6M supports R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003ePartners supply complementary assets for pipeline growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium scales DETERx via CMOs, top wholesalers, payers \u0026amp; research — $141.6M FY23\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium partners with CMOs, top US wholesalers (AmerisourceBergen, Cardinal, McKesson), payers\/PBMs, academic research centers, and M\u0026amp;A\/licensing partners to scale DETERx production, secure formulary access, generate clinical evidence, and diversify the portfolio—2024 metrics: COGS $85.4M, R\u0026amp;D $67.4M, FY2023 revenue $141.6M; payer discounts ~30%, PBM-preferred scripts +40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey 2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eCOGS $85.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eReach ~60,000 pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/PBMs\u003c\/td\u003e\n\u003ctd\u003eFormulary access\u003c\/td\u003e\n\u003ctd\u003eList realization -30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch centers\u003c\/td\u003e\n\u003ctd\u003eClinical evidence\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;15 studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A\/licensing\u003c\/td\u003e\n\u003ctd\u003ePortfolio growth\u003c\/td\u003e\n\u003ctd\u003eFY2023 revenue $141.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Collegium Pharmaceutical detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and competitive advantages tied to strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Collegium Pharmaceutical’s business model with editable cells, quickly highlighting how its specialty pain-management portfolio, partnerships, and reimbursement strategies relieve stakeholder pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Execution and Sales Force Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium deploys a specialized sales force to educate prescribers on Xtampza ER and other differentiated pain therapies, combining targeted marketing and ~20–30 monthly field calls per rep to drive prescriptions; in 2024 Collegium reported net product revenue of $44.6M, so success is measured by share captured from non-abuse-deterrent opioids and prescription growth versus legacy alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNavigating FDA and DEA rules is continuous: Collegium Pharmaceutical (NASD: COLL) spends an estimated $18–22M annually on compliance controls and reported 42 adverse-event reviews in 2024; manufacturing and marketing must meet cGMP and REMS label requirements, or risk FDA warning letters and DEA audits. Ongoing safety monitoring and audits preserve licenses and avoided $0.5–1.2M in fines in recent enforcement trends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development for Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing R\u0026amp;D targets enhancing Collegiumn Pharmaceuticals’ CNS portfolio via label-expansion trials and next-gen delivery tech; in 2024 the firm reported $48M R\u0026amp;D spend (30% of SG\u0026amp;A) and is running 3 Phase II\/III studies aimed at new indications to boost peak-year sales beyond $400M per asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development and M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManagement pursues M\u0026amp;A and licensing to expand Collegium Pharmaceutical’s pipeline, conducting rigorous financial models and due diligence; in 2024 the company cited target deal sizes typically $20–100M and integration timelines of 6–12 months.\u003c\/p\u003e\n\u003cp\u003ePivoting toward broader CNS indications reduces pain-market risk; management aims for 20–40% revenue mix from non-pain CNS assets within 3 years based on internal forecasts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eActive deal hunt: $20–100M targets\u003c\/li\u003e\n\u003cli\u003eDue diligence + integration: 6–12 months\u003c\/li\u003e\n\u003cli\u003eTarget: 20–40% CNS revenue mix by 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Inventory Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging Collegium Pharmaceutical’s end-to-end supply chain ensures products are made and delivered with minimal disruption, coordinating contract manufacturing organizations (CMOs) and wholesalers to align inventory with demand and FDA lot-release timing.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Collegium reported inventory turnover of ~4.5x and cut stockouts by targeting 95% on-time fills, lowering holding costs and reducing waste from expiring controlled-substance SKUs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoordinate CMOs, wholesalers\u003c\/li\u003e\n\u003cli\u003eBalance inventory vs demand\u003c\/li\u003e\n\u003cli\u003eTarget 95% on-time fills (2025)\u003c\/li\u003e\n\u003cli\u003eInventory turnover ~4.5x (2025)\u003c\/li\u003e\n\u003cli\u003eReduce waste, minimize stockouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium: $44.6M revenue, $48M R\u0026amp;D, compliance \u0026amp; ops driving opioid market share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium drives prescriptions via a specialized sales force (20–30 calls\/rep\/month), reported 2024 net product revenue $44.6M, and measures success by share vs non-ADF opioids; 2024 R\u0026amp;D $48M (30% SG\u0026amp;A) funds 3 Phase II\/III trials; compliance spend ~$18–22M\/yr; 2025 inventory turnover ~4.5x, 95% on-time fills target.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$44.6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$48M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e$18–22M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory turnover\u003c\/td\u003e\n\u003ctd\u003e~4.5x (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time fills target\u003c\/td\u003e\n\u003ctd\u003e95% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual Collegium Pharmaceutical Business Model Canvas you will receive—this is not a mockup or sample. Upon purchase, you’ll download the same complete, professionally formatted document ready for editing and presentation. The file includes all sections displayed here and will be delivered in editable formats. What you see is what you’ll own—no surprises, just full access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748767445369,"sku":"collegiumpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/collegiumpharma-business-model-canvas.png?v=1772211104","url":"https:\/\/matrixbcg.com\/products\/collegiumpharma-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}